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Abstract Drug resistance in protozoan parasites has been
associated with the P-glycoprotein (Pgp), an energy-
dependent efflux pump that transports substances across the
membrane. Interestingly, the genes TcPGP1 and TcPGP2 have
been described in Trypanosoma cruzi, although the function of
these genes has not been fully elucidated. The main goal of this
work was to investigate Pgp efflux pump activity and expres-
sion in T. cruzi lines submitted to in vitro induced resistance to
the compounds 4-N-(2-methoxy styryl)-thiosemicarbazone
(2-Meotio) and benznidazole (Bz) and to verify the stability
of the resistant phenotypes during the parasite life cycle. We
observed that the EC50 values for the treatment of
epimastigotes with 2-Meotio or Bz were increased at least
4.7-fold in resistant lines, and this phenotype was maintained
in metacyclic trypomastigotes, cell-derived trypomastigotes,
and intracellular amastigotes. However, in epimastigotes,
2-Meotio resistance is reversible, but Bz resistance is irrevers-
ible. When compared with the parental line, the resistant lines
exhibited higher Pgp efflux activity, reversion of the resistant
phenotypes in the presence of Pgp inhibitors, cross-resistance
with Pgp modulators, higher basal Pgp ATPase activity, and
overexpression of the genes TcPGP1 and TcPGP2. In conclu-
sion, the resistance induced in T. cruzi by the compounds
2-Meotio and Bz is maintained during the entire parasite life
cycle. Furthermore, our data suggest the participation of the
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Chagas disease, caused by the protozoan parasite Trypanosoma
(Schizotrypanum) cruzi, is endemic in Latin America and
affects approximately 10 million people (WHO 2010).
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Additionally, the prevalence of the disease has been increasing
in non-endemic areas such as North America (Bern et al. 2011)
and Europe (Muñoz et al. 2009; Jackson et al. 2010) due to
human migration. The only available drugs for the treatment of
Chagas disease are benznidazole and nifurtimox, which have
limited efficacy during the chronic phase of the infection, require
long treatment periods, and have potentially harmful side effects
(Castro et al. 2006; Caldas et al. 2008). In addition, several T.
cruzi strains have shown to be naturally resistant to these com-
pounds (Filardi andBrener 1987), and the resistancemay also be
induced by maintaining the parasite under prolonged drug pres-
sure (Nirdé et al. 1995; Dos Santos et al. 2008).
The need for a safer and more efficient compound for the
treatment of Chagas disease than current alternatives has led
several groups to study the trypanocidal properties of natural
and synthetic compounds (Campos et al. 2010; Dos Santos
Gomes et al. 2012). Recently, Soares et al. (2011) verified that
the synthetic compound 4-N-(2 ′-methoxy styryl)-
thiosemicarbazone has a potent and selective cytotoxic effect
on different developmental forms of T. cruzi, encouraging its
use in further studies that are focused on finding new treat-
ments for the disease. However, studies have shown that
prolonged treatment with thiosemicarbazones in cancer cell
lines may induce resistance and that this phenotype is associ-
ated with overexpression of the mdr-1 gene, which codes for
the P-glycoprotein (Pgp) (Rappa et al. 1997; Liu et al. 2009).
Pgp (also known as ABCB1) is a transmembrane protein
that belongs to the superfamily of ABC transporters and acts
as an energy-dependent efflux pump to transport substances
across membranes (Higgins 1992). This protein has been
associated with the multidrug resistance phenotype (MDR),
which is characterized by cross-resistance to multiple
unrelated cytotoxic agents in tumor cells (Shustik et al.
1995) and protozoan parasites such as Plasmodium
falciparum (Wilson et al. 1993), Leishmania tropica
(Gamarro et al. 1994), Leishmania amazonensis (Gueiros-
Filho et al. 1995), and Entamoeba histolytica (Descoteaux et
al. 1995). Interestingly, the mdr-like genes TcPGP1 (Torres
et al. 1999) and TcPGP2 (Dallagiovanna et al. 1996) have
been described in T. cruzi, although their drug efflux
activity has not been investigated. In the present work,
we examined whether the T. cruzi Y strain would de-
velop resistance to thiosemicarbazone and benznidazole
(Bz) in vitro and maintain this phenotype through its
life cycle, and studied the association between drug resis-
tance and the activity and expression of P-glycoprotein
in this parasite.
Material and methods
Unless specifically indicated otherwise, all reagents were
acquired from Sigma Aldrich, Brazil.
Parasite
T. cruzi epimastigotes, Y strain (Silva and Nussenzweig
1953), were cultivated at 26 °C in liver infusion tryptose
medium (LIT medium) supplemented with 10 % heat-
inactivated fetal calf serum, 100 U/mL penicillin, and
100 mg/mL streptomycin. The epimastigote forms were
collected during the log phase of cell culture growth.
Effect of the compounds on T. cruzi epimastigotes
Epimastigote forms (final concentration of 5×106/mL) were
incubated in LIT medium in the presence of the compounds 4-
N-(2-methoxy styryl)-thiosemicarbazone (2-Meotio) (Soares
et al. 2011) or Bz (N-Benzyl-2-nitro-1H-imidazole-1-acet-
amide, Roche, Brazil) prepared in dimethylsulfoxide
(Merck, Germany) at concentrations ranging from 25 to
400 μM (the final solvent concentration did not exceed 1.
6 %). The bioassays were performed at 26 °C/24 h in 96-well
plates. The cells were counted using a Neubauer chamber to
determine the EC50 values, corresponding to the effective dose
that kills 50 % of the parasites. Untreated parasites were used
as controls.
Induction of resistance to Bz or 2-Meotio in T. cruzi
epimastigotes
T. cruzi epimastigotes were seeded at 5×106/mL in LIT
medium containing 2-Meotio or Bz at their respective
EC50 concentrations, 71.7 and 182.1 μM. After 24 h, the
medium was replaced with LIT not containing any drug,
allowing the replication of surviving parasites. Seven-day-
old culture parasites were then submitted to the same re-
spective drug concentrations, and this operation was repeat-
ed for ten weekly passages before increasing the drug level
(Nirdé et al. 1995). From the 11th passage onwards, the drug
concentration used to induce resistance was gradually in-
creased in 10-μM steps until the 15th passage was reached.
Resistance induction was analyzed by performing a new
screening after each passage and comparing the EC50
values. The persistence of the resistant phenotypes was
evaluated by cultivating the parasites in vitro without drug
pressure for 6 months.
Effect on metacyclic and cell-derived trypomastigotes
To determine whether the resistance would be maintained
throughout the parasite life cycle, parental and resistant
epimastigotes were cultivated in LIT medium without reposi-
tion for 20 days, and the resulting nutritional stress allowed
their transformation to metacyclic trypomastigotes. Aiming to
kill the remaining epimastigotes, the parasites were treated
with 10 % human serum diluted in RPMI-1640 medium for
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30 min at 37 °C. After morphological transformation, the
parasites were fixed and stained using the Panótico Rápido
kit (Laborclin, Pinhais, Parana, Brazil) and examined using
light microscopy. Metacyclic trypomastigotes were utilized
for (a) a screening assay using the compounds Bz and 2-
Meotio, (b) infection of LLC-MK2 cells (1×106 para-
sites/1×105 cells) to obtain cell-derived trypomastigotes, and
(c) infection of peritoneal macrophages to obtain intracellular
amastigotes. The screening protocol for both metacyclic and
cell-derived trypomastigotes was the same as those used for
the epimastigote forms except for the incubation conditions
(37 °C in a 5 % CO2 atmosphere at 98 % humidity).
Growth inhibition of intracellular amastigotes
Macrophages were isolated from the peritoneal cavity of
Balb/c mice in cold RPMI 1640 medium supplemented with
10 % FCS and 2 mM L-glutamine, 100 U/mL penicillin, and
100 mg/mL streptomycin The cells (2×106 per well) were
maintained at 37 °C in a humidified 5 % CO2 atmosphere. All
assays were carried out using a protocol that was approved by
the animal use ethical committee (Comissão de Ética no Uso
de Animais CEUA/Fiocruz (P-369/07L-013/08)). These cells
were utilized in the following assays:
Cytotoxicity
The cells were treated with 2-Meotio or Bz at various
concentrations (12.5 to 50 μM) for 24 h, and their viability
was measured using the 3-[4,5-dimethylthiazol-2-yl]-2,5-
diphenyl-tetrazolium bromide dye reduction assay as de-
scribed by Mosmann (1983). The absorbance was measured
at 490 nm using a VERSAmax tunable spectrophotometer
(Molecular Devices, Sunnyvale, CA, USA).
Effect on intracellular amastigotes
The macrophages were plated in Lab-Tek tissue chamber
slides and infected with 2×107 metacyclic trypomastigote
forms of parental or resistant lines for 3 h. After this time,
the cells were cultured in RPMI medium in the absence or
presence of various drug concentrations (12.5 to 50 μM) for
24 h. The cultures were fixed with methanol, stained (with
Panótico Rápido as described above), and analyzed using
optical microscopy. The intracellular amastigotes were quan-
tified as the mean±SD of three experiments carried out in
duplicate, and the drug activity was analyzed as the endocytic
index (number of parasites/100 cells) (Silva et al. 2007).
Rhodamine 123 efflux assay
The parental and resistant lines were resuspended at a den-
sity of 5×106 parasites/mL in phosphate-buffered saline
(PBS), and the resistant lines were incubated at 26 °C for
15 min in the presence or absence of 2 μM of the Pgp
inhibitors verapamil or cyclosporin A (Búa et al. 2008).
The parasites were then pelleted at 2,000×g for 10 min,
resuspended in 1 ml PBS containing 20 μg/mL of
Rhodamine 123 fluorescent probe, and incubated for 5 min
at 26 °C. The parasites were washed twice with ice-cold
PBS, and the fluorescence was measured at excitation and
emission wavelengths of 485 and 530 nm, respectively,
using a FACSCalibur flow cytometer (BD Biosciences,
San Jose, CA, USA). Experiments were performed using
duplicate samples in four independent experiments, and the
data were analyzed using Summit software (Dako Colorado
Inc., Fort Collins, CO, USA).
Reversion of resistance and cross-resistance assays
To investigate whether co-treatment of the parasites with Bz
or 2-Meotio plus Pgp inhibitors would revert the resistant
phenotype, epimastigote forms of parental and resistant
lines were treated with the compounds 2-Meotio or Bz in
the presence of 2 μM of verapamil or 2 μM of cyclosporin
A for 24 h at 26 °C. The treatment of parental, M15 and B15
lines with only 2 μM of verapamil or 2 μM of cyclosporin A
was performed as a control. The effect of daunorubicin,
paclitaxel, and vinblastine on parental and resistant lines
was evaluated to verify whether the parasites that were
resistant to Bz or 2-Meotio were also resistant to Pgp mod-
ulators. Both assays were performed using the same proto-
col described in “Effect of the compounds on T. cruzi
epimastigotes” section.
Pgp ATPase activity assay
The abilities of compounds to stimulate ATP hydrolysis
were examined using recombinant human Pgp mem-
branes and measured using the Pgp-Glo™ Assay kit
(Promega, Madison, WI, USA). Briefly, 25 μg of Pgp
was incubated with a range of Bz or 2-Meotio concen-
trations (25–800 μM) in the presence of MgATP (5 mM)
for 40 min at 37 °C. Sodium orthovanadate (SOV, an
ATPase activity inhibitor) was assayed in parallel. SOV-
sensitive ATP hydrolysis was determined by subtracting the
value obtained using the SOV co-incubated Pgp membrane to
those obtained using the SOV-free Pgp membrane. The reac-
tion was measured using a GloMax®-Multi Microplate
Luminometer (Promega, Madison, WI, USA). The EC50 (the
concentration that stimulates 50 % of ATPase activity) was
calculated.
The T. cruzi membrane fractions used were obtained from
epimastigote forms of T. cruzi parental and resistant lines.
Parasites (1×1010) were resuspended in hypotonic lysis buffer
(10 mM Tris–HCl pH 7.4–7.6, 10 mMNaCl, 1.5 mMMgCl2,
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and 1 mM dithiothreitol) and mechanically lysed as described
by Previato et al. (1998). After differential centrifugation
(1,500×g, 10 min and 4 °C), the unbroken cells and nuclei
were removed, and the enriched membrane fraction was
obtained according to Lux et al. (2000). The protein
concentration was measured using the Bradford method
(Bio-Rad Protein Assay kit, Hercules, CA, USA), and
the samples were stored at −20 °C until use. These
fractions were incubated with MgATP (5 mM) for
40 min at 37 °C in the presence or absence of Bz (182.
1 μM) or 2-Meotio (71.7 μM). In parallel, the fractions
were incubated with 100 μM cyclosporin A (a specific
Pgp ATPase inhibitor). Cyclosporin A-sensitive ATP hy-
drolysis was determined by subtracting the value obtained
using the cyclosporin A co-incubated membrane fraction
with that obtained using the Cyclosporin A-free membrane
fraction. The ATPase activity of the parental and resistant
lines was also evaluated in the presence of non-Pgp
ATPase inhibitors [AEO solution: sodium azide, EGTA
and ouabain, together with verapamil (a well-known Pgp
ATPase activity stimulator) (Ambudkar 1998)].
RNA extraction and quantitative real-time RT-PCR
Total RNAs from parental and resistant lines of T. cruzi
epimastigotes were extracted using TRIzol reagent
(Invitrogen, Carlsbad, CA, USA). The 143- and 136-bp
segments corresponding to the TcPGP1 (GenBank ID:
U95956) and TcPGP2 (GenBank ID: Z49222) genes, re-
spectively, were amplified using the following primers:
TcPGP1-forward 5′-GATGCCGATGACGGGATG-3′ and
TcPGP1-reverse 5′-TCG GTACAAATGTGGAGATGG-3′;
TcPGP2-forward 5′-TGGCGTTGT TTATTG TGC-3′ and
TcPGP2-reverse 5 ′-GCCACAAGGCACTTCTC-3 ′ .
Reverse transcription was carried out using the SuperScript
III First-Strand Synthesis System for RT-PCR (Invitrogen,
USA). Quantitative real-time RT-PCR was conducted using
an ABIPRISM 7500 Sequence Detection System (Applied
Biosystems, Foster City, CA, USA) using the Power SYBR
Green PCR Master Mix (Applied Biosystems, USA) in a
final volume of 25 μL according to the manufacturer’s
specifications. A reaction mixture was prepared containing
1 μL of cDNA from each sample mixed with 12.5 μL of 2×
Power SYBR Green PCR Master Mix and 1 μL of each
primer (400 nmolar/rx) in a final volume of 25 μL. The
cDNA was amplified at 95 °C for 10 min followed by
40 cycles of 95 °C for 15 s and 60 °C for 1 min. A reverse
transcription negative control (without reverse transcriptase)
and a non-template negative control were included for each
primer set to confirm the absence of genomic DNA and to
test for primer dimers and contamination in the reactions,
respectively. To ensure that only a single product was am-
plified, a melting curve analysis was performed. Relative
mRNA levels were normalized against the level of β actin
(internal reference) mRNA. All data were expressed as the
mean±SD of three independent experiments (each in
triplicate).
Statistical analysis
Statistical analyses were performed using one-way analysis
of variance and Bonferroni’s test (GraphPad Software, La
Jolla, CA, USA). Differences were considered significant
when p<0.05.
Results
Drug resistance induction and follow-up during the T. cruzi
life cycle
The EC50 value for the treatment of epimastigotes with 2-
Meotio increased from 71.7 to 350.7 μM by the 15th passage
under drug pressure. At the same time, the EC50 value for the
treatment with Bz was 4.7-fold higher in the resistant line
(Table 1). The resistant lines obtained after the 15th passage
were termed M15 (resistant to 2-Meotio) and B15 (resistant to
Bz). The resistance induced in the epimastigotes was
maintained after transformation to metacyclic trypomastigotes,
cell-derived trypomastigotes, and intracellular amastigotes in
both the M15 and B15 lines, as seen from the significant
increase in EC50 values (Table 2). Additionally, the treatment
with 2-Meotio (from 12.5 to 50 μM) did not reduce the
endocytic index in cells infected with the M15 line as it did
in those infected with the parental line (Fig. 1A, B).
Similar results were obtained for the treatment with Bz
Table 1 Induction of resistance to thiosemicarbazone and benznidazole
in T. cruzi epimastigotes
Passagesa ED50/24h (μM)b
2-Meotio Bz






15th 350.7±11.2 c 863.3±53.0 d
a Number of consecutive passages (in vitro) in the presence of each
compound
bMean±SD of at least three independent experiments
c T. cruzi line resistant to 2-Meotio (M15)
d T. cruzi line resistant to Bz (B15)
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for cells infected with the parental or B15 lines, show-
ing that the resistant phenotype was maintained (Fig.
1C, D). From the fourth month of cultivation in the
absence of drug onwards, a continuous decrease in the
EC50 value was observed for the treatment with 2-
Meotio in the M15 line, until it reached the same value
as that observed for the parental line (Figs. 2a), indi-
cating reversibility of the resistance. On the other hand,
the resistance to Bz was maintained even after 6 months
of cultivation without drug pressure (Fig. 2b), indicating
irreversible resistance.
Pgp efflux activity
To investigate the association between Pgp activity and T.
cruzi drug resistance, we performed a Rhodamine 123 fluo-
rescence assay. This molecular probe mimics some Pgp











































Fig. 1 A The effect of 50 μM 2-Meotio on the interaction between
peritoneal macrophages and parental or resistant lines of T. cruzi (Y strain)
for 24 h. a, b Parental line untreated and treated with 2-Meotio. c, d M15
line untreated and treated with 2-Meotio. Magnification ×40. B Endocytic
Index (the percentage of infected cells versus the number of intracellular
amastigotes) for the treatment of T. cruzi with 2-Meotio. C The effect of
50 μM benznidazole (Bz) on the interaction of peritoneal macrophages
with parental or resistant lines of T. cruzi (Y strain) for 24 h. a, b Parental
line untreated and treated with Bz. c, d B15 line untreated and treated with
Bz.Magnification ×40.DEndocytic Index for the treatment of T. cruziwith
Bz for 24 h. Asterisk, significant difference in the parental line when
comparing the endocytic index in the treated group versus the control
Table 2 Persistence of drug-re-
sistant phenotype during T. cruzi
life cycle
aMean±SD of at least three in-
dependent experiments




Developmental stage 2-Meotio Bz
Parental M15 Parental B15
Epimastigote 71.7±4.4 350.7±11.2 182.1±10.7 863.3±53.0
Metacyclic trypomastigote 20.4±1.2 44.2±2.2 77.3±5.1 177.4±13.0
Culture-derived trypomastigote 16.7±3.7 50.3±6.5 21.1±1.7 64.9±2.7
Intracellular amastigotesb 40.9±3.6 56.8±6.8 48.4±1.3 71.2±6.1
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activity in parasite and human cell lines (Gueiros-Filho et al.
1995; Gupta et al. 2011).
Figure 3 shows that the fluorescence exhibited by the
M15 and B15 lines was, respectively, 39.4 and 50.8 % lower
than that exhibited by the parental line, indicating that there
was an efflux of Rhodamine by the resistant parasites.
Furthermore, Rhodamine fluorescence inside the resistant
lines increased significantly after treatment with the Pgp
inhibitors cyclosporin A (CsA; Fig. 3a, b) or verapamil
(VP; Fig. 3c, d) due to inhibition of the Pgp efflux activity.
To determine whether the resistance phenotype was revers-
ible, the M15 line was co-treated with 2-Meotio plus either
CsA or VP (Fig. 3e), and the B15 line was co-treated with Bz
plus either CsA or VP (Fig. 3f) in the screening assay. A
significant reduction of the EC50 values was observed in com-
parison with the treatments with 2-Meotio alone (Fig. 3e) or Bz
alone (Fig. 3f). In a parallel experiment, it was observed that the
treatment with 2 μMVP alone or 2 μMCA alone did not affect
parasite proliferation.
In the cross-resistance assay, it was shown that the M15
line, which is resistant to 2-Meotio, is also more resistant to
the compounds Bz, vinblastine, and daunorubicin than is the
parental line. It was also observed that the B15 line is more
resistant not only to Bz but also to the Pgp modulators
vinblastine, paclitaxel, and daunorubicin compared to the
parental line (Table 3).
Pgp ATPase activity
The effect of various concentrations of 2-Meotio and Bz
on recombinant human Pgp ATPase activity was evaluat-
ed. Both compounds stimulated ATPase activity with EC50
values of 134 and 277.1 μM, respectively [i.e., concen-
trations that cause a 50 % increase in Pgp ATPase activity
(Fig. 4a)]. The effects of cyclosporin A and the AEO
solution (which contains three ATPase inhibitors; see
“Material and methods” section) were also tested. Verapamil
was used as a positive control. Verapamil stimulates, cyclo-
sporin A inhibits, and the AEO solution has no effect on Pgp
ATPase activity (see Appendix). Subsequently, the Pgp
ATPase activity of T. cruzi-enriched membrane fractions was
analyzed. Higher basal Pgp ATPase activity was observed in
the membrane fractions of the resistant lines M15 and B15
compared with that observed in the parental line (Fig. 4b, c).
In addition, the compounds 2-Meotio or Bz stimulated ATP
hydrolyses in the resistant lines M15 and B15, respectively. In
parallel, basal Pgp ATPase activity was also evaluated by
measuring ATPase activity in the presence of the AEO solu-
tion, which inhibits only non-Pgp ATPases, and the previous
results were corroborated (see Appendix).
Pgp expression assay
The expression of the TcPGP1 gene was 1.7-fold higher in
the B15 line and 2.7-fold higher in the M15 line than in the
parental line. Similarly, the expression of the TcPGP2 gene
was 1.6-fold higher in the B15 line and 1.5-fold higher in
the M15 line than in the parental line (Fig. 5).
Discussion
Drug resistance in T. cruzi is considered a major problem for
the treatment of Chagas disease, not only because of the
natural resistance of some strains to benznidazole (Andrade
et al. 1985; Toledo et al. 1997) but also because of the ability
of this drug to induce resistance in T. cruzi experimentally
(Murta and Romanha 1998). This easily achieved resistance
phenotype may be associated with the therapeutic failures
observed during the chronic phase of the illness because
long-term treatment is required to control the infection. In this
study, we demonstrated that both benznidazole and the
thiosemicarbazone 2-Meotio can induce resistance in the Y
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Fig. 2 Maintenance of T. cruzi drug resistance after its cultivation
without drug pressure. T. cruzi epimastigotes from the parental line and
the resistant linesM15 (a) or B15 (b) were cultivated in vitro for 6 months
without drug pressure. The concentrations of 2-Meotio or benznidazole
that kill 50 % of the parasites (EC50) were calculated monthly to deter-
mine whether the resistance was maintained. Control refers to the resistant
parasites obtained after the 15th passage in the presence of each com-
pound. Asterisk, significant differences between the EC50 values for the
M15 and B15 lines compared to the parental line
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Resistance to various types of thiosemicarbazones in
cancer cell lines has been extensively investigated and
appears to be mediated by either qualitative or quanti-
tative alterations in P-glycoprotein. Rappa et al. (1997)
reported that resistance to 3AP in L1210 MQ-580 cells
is associated with the overexpression of the multidrug
resistance gene mdrl. Likewise, Pgp overexpression has also
been demonstrated in cancer cell lines that are resistant to the







































































Fig. 3 Histograms showing Rhodamine 123 fluorescence in T. cruzi
epimastigotes. Parental line and resistant lines untreated or treated with
the Pgp inhibitors cyclosporin A (CsA; a, b) or verapamil (VP; c, d).
Reversion of epimastigote resistance by co-treatment with 2-Meotio or
Bz plus Pgp inhibitors. The EC50 values for the treatment of the
parental and M15 lines with 2-Meotio plus 2 μM of CsA or VP (e)
and the treatment of the parental and B15 lines with Bz plus 2 μM of
CsA or VP were measured (f). Asterisk, significant difference for the
lines M15 (e) or B15 (f) comparing the EC50 values obtained after
treatment with 2-Meotio or Bz alone, and in the presence of Pgp
inhibitors
Table 3 Cross-resistance assay
aMean±SD of at least three in-
dependent experiments
bSignificant difference for each




2-Meotio Bz Vinblastine Paclitaxel Daunorubicin
Parental 71.7±4.4 182.1±10.7 79.5±8.2 12.9±2.3 799.7±73.1
M15 350.7±11.2b 345.5±14.9 b 144.2±10.7 b 14.5±5.3 1,219.7±97.7 b
B15 80.3±6.1 863.3±53.0 b 296.7±18.3 b 57.4±5.2 b 1,884.8±152.8 b
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compoundsMAIQ (Cory et al. 1997) and 64Cu-ATSM (Liu et
al. 2009). In addition, qualitative modifications, such as
polymorphism of the mdr1 gene, can also result in resistance
to thiosemicarbazones (Choi et al. 2010; Traynor et al. 2010).
In T. cruzi epimastigotes (Y strain), P-glycoprotein is
encoded by two genes, TcPGP1(Torres et al. 1999) and
TcPGP2 (Dallagiovanna et al. 1996); both of these genes are
presented as a single copy. However, little is known about the
physiological role of this protein inside the parasite. It has been
suggested that Pgp is involved in the trafficking of
heme through the plasma membrane (Lara et al. 2007;
Cupello et al. 2011). Our data suggest that this ABCB1
efflux pump is involved in T. cruzi drug resistance. It
was demonstrated that the resistance to 2-Meotio and
benznidazole in epimastigotes is associated with Pgp
efflux activity, Pgp ATPase activity, and overexpression
of the TcPGP1 and TcPGP2 genes. We also observed
that cross-resistance occurs between the studied com-
pounds and some Pgp modulators. These findings are
in agreement with the MDR phenotype mediated by
Pgp (Ambudkar et al. 1999). Moreover, considering
that ATP binding and hydrolysis are recognized as
essential conditions for the drug transport activity of
Pgp (Horio et al. 1988; Scarborough 1995), the ability
of both 2-Meotio and Bz to stimulate Pgp ATPase







































































































EC50 2-Meotio = 134 µM




Fig. 4 The effect of various concentrations of 2-Meotio or Bz on
recombinant human Pgp ATPase activity (a). Pgp ATPase activity in
the membrane fraction of Parental and M15 lines (b) or parental and
B15 lines (c). The basal Pgp ATPase activity was calculated based on
the difference between ATPase activity in the untreated sample and in
the presence of cyclosporin A (CsA; 100 μM). The effect of 2-Meotio
(71.7 μM) (b) or Bz (182.1 μM) (c) on Pgp ATPase activity was
calculated based on the difference in ATPase activity in the presence
of each compound alone (Bz or 2-Meotio) and the compound plus CsA
(Bz+CsA or 2-Meotio+CsA). The results are expressed as nanomoles
of ATP consumed in the reaction. Asterisk, significant difference for
the comparison of basal ATP consumption between the parental line
and the lines M15 (b) or B15 (c). Double asterisk, significant differ-
ence for the comparison of ATP consumption with and without treat-



























Fig. 5 Relative gene expression of the TcPGP 1 and TcPGP2 tcpgp2
genes in the parental and resistant lines of T. cruzi quantified using
real-time PCR. The values were normalized to the level of the β-actin
gene and expressed as arbitrary units. The values shown are the mean±
SD of three experiments performed in triplicate. Asterisk, relative gene
expression was compared between M15 and parental lines, or B15 and
parental lines. Differences between the values were considered signif-
icant when the increase in the gene expression was at least 1.5-fold
higher
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substrates. Additionally, this is the first study to de-
scribe Pgp efflux activity and Pgp ATPase activity in T.
cruzi, and this finding may contribute to an improved
understanding of the biochemical properties of Pgp in
this parasite.
Considering that the resistance phenotype was maintained
throughout the entire parasite life cycle, an association between
Pgp and drug resistance in the other developmental forms of T.
cruzi can be proposed. Dallagiovanna et al. (1996) have identi-
fied the gene TcPGP2 not only in epimastigote forms but also in
intracellular amastigotes. However, the TcPGP1 gene has been
studied only in the epimastigotes of T. cruzi (Torres et al. 1999).
For this reason, its identification in the trypomastigote and
amastigote forms should be investigated.
Despite the participation of Pgp in the common drug
resistance mechanism between lines M15 and B15, these
lines differed in the stability of the resistance phenotype in
the absence of drug, most likely due to differences in the
overall pattern of protein expression. This fact supports the
existence of more than one mechanism that act in concert to
provide drug resistance in T. cruzi. Studies regarding drug
resistance to Bz have reported the participation of proteins
associated with parasite metabolism (Portal et al. 2008;
Campos et al. 2009) and antioxidant defense (Nogueira et
al. 2009; Murta et al. 2008). Alterations in the expression of
proteins related to drug metabolism have also been observed
(Murta et al. 2006; Mejía-Jaramillo et al. 2011; Mejia et al.
2012). However, an association between Pgp expression and
drug resistance has not been found (Murta et al. 2001).
Nevertheless, some authors suggest that the in vivo and in
vitro resistance to Bz operate through different mechanisms
(Andrade et al. 2008; Villarreal et al. 2005). Until now, the
existence of a common drug resistance mechanism has not
been described either inside each genetic cluster of T. cruzi or
among natural and laboratory-selected resistant lines (Dos
Santos et al. 2008).
Interestingly, it was demonstrated that the first generation
Pgp inhibitors cyclosporin A and verapamil were able to
revert drug resistance to 2-Meotio and Bz in T. cruzi. Similar
results have been described by Neal et al. (1989) who ob-
served that co-treatment with nifurtimox and verapamil effec-
tively reversed resistance to nifurtimox in the T. cruzi X10
clone in vitro. Thus, one approach that might be explored for
the treatment of Chagas disease is to use a combination of
drugs with Pgp reversal agents to prevent the emergence of the
Pgp-mediated MDR phenotype. Clinical trials using Pgp re-
versal agents have been performed to overcome drug resis-
tance in cancer cell lines (Sonneveld et al. 2001; Morjani and
Madoulet 2010). Second-, third-, and fourth-generation Pgp
inhibitors have been investigated; the last group is considered
the most promising because drugs in this group exhibit higher
affinity to Pgp and lower toxicity to normal mammal cells
(Palmeira et al. 2012).
Conclusions
Inducing in vitro resistance to benznidazole in the Y strain of
T. cruzi provided an additional model to not only study the
characteristics of the resistance phenotype but also evaluate
the effect of new compounds on this parasite. Furthermore,
our data suggest that the Pgp efflux pump plays a role in T.
cruzi drug resistance. Knowledge of the mechanism of drug
resistance in T. cruzi may be helpful for further studies that
focus on new drug targets and drug associations aimed at
improving the treatment of Chagas disease.
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Appendix
Fig. 6 The effects of verapamil, AEO solution, and cyclosporin A on
recombinant human Pgp membrane. Description of data: Standardiza-
tion of the assay, confirming that verapamil stimulates, cyclosporin A
inhibits, and the AEO solution has no effect on Pgp ATPase activity.
The effect of these agents on ATP consumption was compared with
basal ATP consumption (which was measured based on the difference
between ATP consumption in the presence and absence of sodium
orthovanadate, a Pgp ATPase activity inhibitor)
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